Ye L, et al. - In this retrospective analysis, researchers compared the efficacy and toxicity of decitabine vs low-dose chemotherapy in the treatment of myelodysplastic syndromes (MDS)-refractory anemia with excess blasts (MDS-RAEB) patients Overall 112 patients were included in this study. Findings revealed a comparable overall response (OR) and complete remission (CR) rate between the two groups. Also, comparable OR rates were seen with 20 mg/m²/day and 15 mg/m²/day decitabine regimen. According to the findings, both the treatment options (decitabine and low-dose chemotherapy) effectively treated MDS-RAEB patients but decitabine was safer. For the treatment of patients at ≥60 years of age, decitabine might be a better option.